NANCY DENYES - 03 Feb 2022 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
General Counsel
Signature
Nancy E. Denyes
Issuer symbol
LIFE
Transactions as of
03 Feb 2022
Transactions value $
$0
Form type
4
Filing time
07 Feb 2022, 15:59:07 UTC
Previous filing
25 May 2021
Next filing
26 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Employee Stock Option (right to buy) Award $0 +21,500 $0 21,500 03 Feb 2022 Common Stock 21,500 $5.52 Direct F1
transaction LIFE Restricted Stock Units Award $0 +10,750 $0 10,750 03 Feb 2022 Common Stock 10,750 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 3, 2022, such that this option will be fully exercisable on February 3, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs are scheduled to vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.